Twelve Chinese Biopharma Companies Secure Over RMB 2.1 Billion in May 2025, Several Advance Toward IPO

　　【Pharmaceutical Network Industry DynamicsReviewing May 2025, the total number of financing events for biopharmaceutical enterprises in China reached 23, among which 12 companies secured financing exceeding 100 million yuan. The total amount is estimated to be approximately 2.1 billion yuan, covering sectors such as regenerative medicine, innovative drug development, innovative medical devices, and more.
 

From the perspective of financing amounts, Sirius Therapeutics and Haobo Medicine's Series B+ financings are among the highest. On May 9, Sirius Therapeutics announced the successful completion of a nearly US$50 million Series B2 financing round to accelerate the clinical development of its novel small interfering RNA (siRNA) therapies for cardiometabolic diseases and to further innovate its next-generation RNA delivery technology. The company currently has three clinical-stage projects and multiple preclinical product pipelines. Among them, SRSD107, a novel anticoagulant therapy with rapid progress, represents a new generation of long-acting anticoagulants for treating and preventing thromboembolic diseases, and an application for a Phase 2 clinical trial in Europe has been submitted to the European Medicines Agency (EMA). SRSD216, a novel siRNA therapy targeting lipoprotein(a), has received approvals from the U.S. FDA and China’s NMPA and is currently undergoing Phase 1 clinical trials. Another siRNA therapy for hyperlipidemia, SRSD101, is also advancing steadily through clinical development in China.
 

HaoBo Medicine, a developer of small nucleic acid drugs for hepatitis B, announced at the end of May the completion of a US$50 million Series B+ financing round. The investors in this round were Qiming Venture Partners, CDH Investments, Genesis Capital, Yuanbio Venture Capital, Hanking Capital, and Sherpa Healthcare Partners. The company is a clinical-stage innovative drug research and development company, focusing on the development of self-innovative targeted delivery small nucleic acid drugs, and is committed to achieving the goal of clinical cure for chronic hepatitis B.
 

Second is GeneMind's C+ round of 280 million RMB. On May 28, GeneMind announced the completion of its C+ round financing worth 280 million RMB. This round was jointly led by industry leaders in the third-party medical testing sector, including KingMed Diagnostics, as well as institutions such as Sansure Biotech, Saintway Capital, and Jinhe Capital. Other participating investors included Woje Capital, Haikou Junxin, Shuangye Venture Capital, and Qianhe Capital. With this funding, GeneMind will focus on two strategic goals: "commercial ecosystem development" and "global expansion." The investment will provide sufficient momentum for strengthening market presence, expanding production capacity, and ensuring compliance, accelerating dual breakthroughs in domestic substitution and overseas technology export.
 

In addition, EndoCell's Series A round and LongBio's Series C round each raised approximately 200 million RMB. Recently, EndoCell announced the completion of nearly 200 million RMB in financing. This round includes a Series A round led by Shanghai Science and Technology Innovation Group (under Shanghai State-owned Investment Corporation) and Da Linghao Bay Strategy Fund, two state-owned investment entities, as well as a Pre-A+ round led by existing shareholder Leo Group, with joint participation from Pansheng Capital and Jintai Jinhong Fund. The funds will primarily advance the Phase I/II clinical trials of China’s first allogeneic universal regenerative islet pipeline, accelerate the expansion of strategic layout in Asia, and develop new pipelines for diabetes and liver disease treatment.
 

LongBio also announced in May the completion of a Series C financing round exceeding 200 million yuan. This round was jointly led by Hony Capital and existing shareholder Qiming Venture Partners, with participation from Linqing Blue Bay Fund, Beta Fund, Zhenmai Fund, and continued investment from existing shareholders such as Sanyi Capital and Shan Zheng Innovation. The funds from this round will primarily be used for core pipeline development, including Phase III clinical trials and subsequent commercialization preparations for the next-generation anti-IgE antibody LP-003, as well as Phase II clinical development for multiple indications of the complement bispecific antibody LP-005.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.